Matthew Sorrentino
Cardiovascular Disease · Chicago, ILNPI 1215090725
Payments from drug & device makers
Across 13 payments — averaging $2340.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intercept Pharmaceuticals, Inc.$30K
- Abbott$131
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$26
Across 7 payments — averaging $2416.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Intercept Pharmaceuticals, Inc.$17K
What the payments were for
- Consulting fees$30,27399%
- Food & beverage$1571%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intercept Pharmaceuticals, Inc. | 11 | $30,273 |
| Abbott | 1 | $131 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OCALIVA$30,273
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$131
How this compares
$30,430 in reported general payments places this provider in the 85th percentile of 932 cardiovascular disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 287 | $390,330 |
| XareltoRivaroxaban | 77 | $115,292 |
| EntrestoSacubitril/Valsartan | 52 | $88,971 |
| JardianceEmpagliflozin | 60 | $77,328 |
| Repatha SureclickEvolocumab | 62 | $57,196 |
| FarxigaDapagliflozin Propanediol | 20 | $24,769 |
| Praluent PenAlirocumab | 13 | $18,415 |
| Metoprolol Succinate | 483 | $8,262 |
| Atorvastatin Calcium | 427 | $4,855 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 11 | $4,156 |
| Losartan Potassium | 312 | $4,005 |
| Rosuvastatin Calcium | 237 | $3,769 |
| Amlodipine Besylate | 404 | $3,609 |
| Spironolactone | 291 | $3,314 |
| Bumetanide | 86 | $3,099 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Chicago
- Benjamin LumicaoChicago$3.7M
- Paul CremerChicago$2.9M
- Nitasha SarswatChicago$2M
- Sanjiv ShahChicago$1.2M
- Sandeep NathanChicago$1.1M
- Boaz AvitallChicago$663K
- Ravi PatelChicago$488K
- Lubna ChoudhuryChicago$476K
- Akhil NarangChicago$427K
- Amit AminChicago$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.